Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FA0TE
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $62,682
Award facts
- Contract value 100% obligated
- $62,682.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $62,682.22 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections. This competitive award, issued on December 19, 2025, with an ultimate completion date of December 22, 2025, represents a firm fixed-price transaction with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the contractor to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical requirements through open competition, including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. Dupixent is a biologic immunosuppressant used for treating conditions such as atopic dermatitis, asthma, and eosinophilic conditions, making this delivery order part of the Defense Health Agency's broader pharmaceutical supply chain supporting active-duty personnel and beneficiaries.
Quick answers
Who was awarded contract SPE2DR26FA0TE?
SPE2DR26FA0TE was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26FA0TE worth?
The government has obligated $62,682 on SPE2DR26FA0TE.
Is contract SPE2DR26FA0TE an order under another contract?
Yes. SPE2DR26FA0TE is a delivery order under SPE2DR25D2100, an indefinite delivery contract.
Was contract SPE2DR26FA0TE competed?
The extent of competition for SPE2DR26FA0TE was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award